Amyloid-beta immunization in Alzheimer's disease transgenic mouse models and wildtype mice.
Alzheimer's disease is the most prevalent form of dementia worldwide. Therapies are desperately needed to prevent and cure the disease. Mouse models of amyloid-beta deposition [APP and PSAPP transgenic (tg) mice] have been useful in determining the role of amyloid-beta (A beta) in both the pathogenesis and cognitive changes in AD. In addition, they have allowed scientists to investigate potential AD therapies in living animals. Active and passive A beta immunizations have been employed successfully in APP and PSAPP tg mice to lower cerebral A beta levels and improve cognition. Optimization of immunization protocols and characterization of immune responses in wildtype mice have been reported. Based on the promising results of A beta immunization studies in mice, a clinical trial was initiated for A beta vaccination in humans with AD. Although no adverse effects were reported in the Phase I safety trials, about 5% of AD patients in the phase II clinical trial developed meningoencephalitis, ending the trial prematurely in March 2002. Studies in AD mouse models and wildtype mice may help elucidate the mechanism for these unwanted side effects and will be useful for testing newer, safer vaccines for future use in human clinical trials.
Department of Neurology, Center for Neurologic Diseases, Brigham & Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA. lemere@cnd.bwh.harvard.edu
Cynthia A
CA
Lemere
Edward T
ET
Spooner
Jodi F
JF
Leverone
Chica
C
Mori
Melitza
M
Iglesias
Jeanne K
JK
Bloom
Timothy J
TJ
Seabrook
D000544:Alzheimer Disease / Q000517:prevention & control*; D016229:Amyloid beta-Peptides / Q000276:immunology*; D000818:Animals; D000835:Animals, Wild; D006801:Humans; D007114:Immunization; D007116:Immunization, Passive; D051379:Mice; D008822:Mice, Transgenic; D014611:Vaccination
D016229:Amyloid beta-Peptides